REVERT study (design, background, primary, a secondary endpoint, trial enrollment) has been scheduled for presentation in a Poster Session at SABCS 2019 in San Antonio (Texas, USA) December 10-14, 2019.
The abstract was presented as a poster and MedSIR team was there to discuss REVERT study and solve attendance questions.
Currently, the REVERT trial is open and recruiting in 9 sites on Spain.
REVERT is a multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy.
The primary endpoint is the overall response rate in the arm corresponding to the patients treated with eribulin in combination with aromatase inhibitor therapy based on local investigator’s assessment according to RECIST v.1.1
REVERT is a Simon’s two-stage admissible design clinical trial, 60 patients will be included, 22 in stage I and 38 in stage II.
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, alone or in combination with endocrine therapy (aromatase inhibitor).
Thanks to the commitment of all the sites involved in REVERT study, and the constant support from EISAI, we are making an effort to increase the recruitment rate in order to achieve the final analysis.
Author: Noemí López
